Vetera 2XP (Canada)

Company: Boehringer Ingelheim Animal Health

Equine Rhinopneumonitis-Influenza Vaccine

Killed Virus

Vetera 2XP Indications

This product has been shown to be effective for the vaccination of healthy horses 4 months of age or older, including pregnant mares, against respiratory disease due to equine herpesvirus types 1 and 4 (EHV-1 & EHV-4) and A2 equine influenza virus (EIV). The duration of immunity against EIV OH/03 is at least 6 months. The duration for the remaining organisms has not been determined. For more information regarding efficacy and safety data go to productdata.aphis.usda.gov.

This product has also been shown to be effective against shedding due to A2 EIV.

Composition

Contains Kentucky Lineage (KY/95), Florida sublineage clade 1 (OH/03), and Florida sublineage clade 2 (RI/07) EIV strains. Amphotericin B and gentamicin added as preservatives.

Directions and dosage: Shake well before use. Using aseptic technique, inoculate horses intramuscularly with a 1mL dose. Administer a second 1 mL dose intramuscularly in 3 to 4 weeks using a different injection site. Historically, annual revaccination with this product has been recommended. The need for annual booster vaccination has not been established for this product. For advice on revaccination frequency, contact your veterinarian or the manufacturer.

Precautions

Store at 2-8°C. Do not freeze. Do not mix with other products. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Transient local reactions may occur at the injection site. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician.

For use in animals only.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., St. Joseph, MO 64506

Tel: 1 (888) 637-4251

VLN/PCN 124/1515.22

Distributed by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

Vetera^® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.

CPN: 1182196.2